Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC

被引：8
|
作者：
Piotrowska, Zofia
Liu, Stephen V.
Muzikansky, Alona
Marcoux, Nicolas
Banwait, Mandeep
Stevens, Sara
Goodwin, Kelly
Lafferty, Tracey E.
Ackil, Jennifer
Krueger, Elizabeth A.
Heist, Rebecca Suk
Lin, Jessica Jiyeong
Gainor, Justin F.
Hata, Aaron N.
Shaw, Alice Tsang
Sequist, Lecia V.
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[2] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Harvard Med Sch, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e21231
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21231
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression
    White, Maya N.
    Piotrowska, Zofia
    Stirling, Kevin
    Liu, Stephen V.
    Banwait, Mandeep K.
    Cunanan, Kristen
    Sequist, Lecia V.
    Wakelee, Heather A.
    Hausrath, Daniel
    Neal, Joel W.
    [J]. CLINICAL LUNG CANCER, 2021, 22 (03) : 201 - 209
  • [2] Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis.
    Neal, Joel W.
    Hausrath, Daniel
    Wakelee, Heather A.
    Cunanan, Kristen
    Liu, Stephen V.
    Banwait, Mandeep
    Sequist, Lecia V.
    Stirling, Kevin
    Piotrowska, Zofia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
    Cui, Qingli
    Hu, Yanhui
    Cui, Qingan
    Wu, Daoyuan
    Mao, Yuefeng
    Ma, Dongyang
    Liu, Huaimin
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [4] Safety of tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
    Liam, C. K.
    Kim, T. M.
    Yang, J-J.
    Huang, C.
    Voon, P-J.
    Tho, L. M.
    Zhou, Q.
    Wang, J.
    Hayashi, H.
    Tan, D. S. W.
    Danchaivijitr, P.
    Nguyen, V. N.
    Wong, K. H.
    Yang, J. C-H.
    Le, X.
    Ellers-Lenz, B.
    Karachaliou, N.
    Ghori, V.
    Berghoff, K.
    Wu, Y-L.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1691 - S1691
  • [5] Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib
    White, Maya N.
    Piper-Vallillo, Andrew J.
    Gardner, Rebecca M.
    Cunanan, Kristen
    Neal, Joel W.
    Das, Millie
    Padda, Sukhmani K.
    Ramchandran, Kavitha
    Chen, Thomas T.
    Sequist, Lecia, V
    Piotrowska, Zofia
    Wakelee, Heather A.
    [J]. CLINICAL LUNG CANCER, 2022, 23 (03) : E210 - E221
  • [6] Osimertinib Called "Home Run" for EGFR-Mutant NSCLC
    Rose, Suzanne
    [J]. CANCER DISCOVERY, 2020, 10 (07) : 896 - 897
  • [7] Resolving Resistance to Osimertinib by Combining Apatinib and Osimertinib in EGFR-Mutant NSCLC Patients
    Yang, X.
    Zhao, J.
    Liang, L.
    Xu, L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S559 - S559
  • [8] Induction osimertinib in EGFR-mutant stage IIIA/B NSCLC
    Kian, W.
    Roisman, L. C.
    Dudnik, J.
    Chernomordikov, L.
    Allen, A. M.
    Corn, B.
    Dudnik, E.
    Rosenberg, S. K.
    Zemel, M.
    Lavrenkov, K.
    Peled, N.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S941 - S941
  • [9] Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC
    Freydman, Jessica
    Henshaw, Lynnette
    Patel, Jasmine V.
    Smith, Claire E.
    Everett, Peter C.
    [J]. ANNALS OF PHARMACOTHERAPY, 2022, 56 (04) : 503 - 504
  • [10] Efficacy of Osimertinib Continuation Plus Metronomic Oral Vinorelbine for EGFR-mutant Advanced NSCLC Beyond Limited Progression on Osimertinib
    Li, Meifang
    Lin, Cheng
    Lin, Jinghui
    Chen, Shijie
    Weng, Lihong
    He, Zhiyong
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2023, 23 (19) : 2095 - 2101
12345